TY - JOUR
T1 - A century of cholesterol and coronaries
T2 - From plaques to genes to statins
AU - Goldstein, Joseph L.
AU - Brown, Michael S.
N1 - Funding Information:
The authors gratefully acknowledge the many talented students, postdoctoral fellows, and collaborators who have conducted the experiments described from our laboratory. Their names are included in the cited references. Our experimental work over the last 40 years has been supported by grants from the NIH (HL-20948), the Perot Foundation, Moss Heart Foundation, and the O’Donnell Foundation. J.L.G. and M.S.B. are members of the Board of Directors and shareholders in Regeneron Pharmaceuticals.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/3/26
Y1 - 2015/3/26
N2 - One-fourth of all deaths in industrialized countries result from coronary heart disease. A century of research has revealed the essential causative agent: cholesterol-carrying low-density lipoprotein (LDL). LDL is controlled by specific receptors (LDLRs) in liver that remove it from blood. Mutations that eliminate LDLRs raise LDL and cause heart attacks in childhood, whereas mutations that raise LDLRs reduce LDL and diminish heart attacks. If we are to eliminate coronary disease, lowering LDL should be the primary goal. Effective means to achieve this goal are currently available. The key questions are: who to treat, when to treat, and how long to treat.
AB - One-fourth of all deaths in industrialized countries result from coronary heart disease. A century of research has revealed the essential causative agent: cholesterol-carrying low-density lipoprotein (LDL). LDL is controlled by specific receptors (LDLRs) in liver that remove it from blood. Mutations that eliminate LDLRs raise LDL and cause heart attacks in childhood, whereas mutations that raise LDLRs reduce LDL and diminish heart attacks. If we are to eliminate coronary disease, lowering LDL should be the primary goal. Effective means to achieve this goal are currently available. The key questions are: who to treat, when to treat, and how long to treat.
UR - http://www.scopus.com/inward/record.url?scp=84925851378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925851378&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2015.01.036
DO - 10.1016/j.cell.2015.01.036
M3 - Review article
C2 - 25815993
AN - SCOPUS:84925851378
SN - 0092-8674
VL - 161
SP - 161
EP - 172
JO - Cell
JF - Cell
IS - 1
M1 - 8011
ER -